SC

Shanghai Chest Hospital at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Shanghai Chest Hospital takes part in 3 sessions at ESMO 2026 in Madrid. Its sessions centre on non-small cell lung cancer, especially EGFR-mutant disease with MET amplification or overexpression after earlier EGFR-targeted treatment. It presents phase 3 trials comparing MET and EGFR inhibitor combinations with chemotherapy, and final results for toripalimab plus chemotherapy around surgery in resectable disease.

Organization

ESMO 2026 Attendance

SC

Shanghai Chest Hospital

Shanghai, China

Cancer centre & hospital

Specialist hospital for chest diseases, including lung and other thoracic cancers, affiliated with Shanghai Jiao Tong University School of Medicine.

Abstract

Sun Oct 25
16:54–17:06

LBA6 - Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results

Presidential Symposium II

Lung & thoracic cancersGastrointestinal cancers

Abstract

Mon Oct 26
08:40–08:50

2615O - Dalmelitinib plus Aumolertinib versus platinum-based chemotherapy in advanced NSCLC patients with MET amplification post EGFR TKI: a randomized, phase 3 study

Proffered paper 2: NSCLC, metastatic

Lung & thoracic cancers

Abstract

Mon Oct 26
15:23–15:33

LBA64 - Toripalimab plus chemotherapy as perioperative treatment for resectable stage II or III non-small cell lung cancer (NSCLC): Final analysis of the Phase 3 Neotorch study

Proffered paper: Non-metastatic NSCLC and other thoracic malignancies

Lung & thoracic cancers

Instantly find 20 buyers from Shanghai Chest Hospital

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction